Business
RepliCel Selected as One of This Year's Top 20 Public Canadian Technology Companies
RepliCel Selected as One of This Year's Top 20 Public Canadian Technology Companies.
About this update from Replicel Life Sciences Inc.
[{"type":"text","content":"\n\n\n\nRepliCel Selected as One of This Year's Top 20 Public Canadian Technology Companies\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nRepliCel Selected as One of This Year's Top 20 Public Canadian Technology Companies\nCanada NewsWire\nVANCOUVER, Nov. 4, 2015\n\n\n\nCanadian Innovation Exchange (CIX) Public Investor Day November 18 at Toronto's MaRS Discovery District to showcase 'Canada's hottest and most innovative public technology companies'\n\n\n\nVANCOUVER, Nov. 4, 2015 /CNW/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to announce that it has been selected as one of Canada's 'hottest and most innovative public technology companies' by the Canadian Innovation Exchange (CIX).  This elite group of 20 companies was selected by CIX, and its advisory board, who rated all Canadian small- and mid-cap companies based on business model, depth of management, market opportunity and quality of product(s) offered.  RepliCel will be presenting to a large group of professionals in Canada's technology industry including analysts, fund managers, institutional investors, advisors, brokers and the media at the CIX Public Investors Top 20 event on November 18, 2015, at Toronto's MaRS Discovery District between 1:00 pm and 5:30 pm.  \n\n\"We are honored to have been selected as one of this year's 20 most innovative public Canadian technology companies by the CIX organizing committee, and to be the only life sciences company within the group,\" stated Lee Buckler, Vice President of Business & Corporate Development for RepliCel Life Sciences.  \"We look forward to presenting our next-generation dermal injector and innovative platform of cellular therapies to the attendees of the CIX event. The next 15 months represent a very exciting time for RepliCel given its ongoing partnership with Shiseido in Japan, expected clinical data, the anticipated CE mark authorization to market its d...